Literature DB >> 16259011

An essential role for Rxr alpha in the development of Th2 responses.

Xin Du1, Koichi Tabeta, Navjiwan Mann, Karine Crozat, Suzanne Mudd, Bruce Beutler.   

Abstract

A viable hypomorphic allele of mouse retinoid X receptor alpha (Rxralpha) was created by random germline mutagenesis. The mutation (I273N) alters the ligand binding and heterodimerization domain, and causes a 90% decline in ligand-inducible transactivation. Homozygotes develop progressive alopecia and dermal cysts, and progressive exaggeration of Th1 and loss of Th2 responses to antigen. Th1 skewing is directly caused by aberrant function of both antigen-presenting cells and naïve CD4 T cells; the predominant Th1 response to antigen is attributable to decreased suppression of regulatory T cells in mutant mouse. Dietary depletion of vitamin A in Th2-prone wild-type mice mimics the immune phenotype caused by the mutation. Hence, RXRalpha plays an important post-developmental role in the regulation of adaptive immune responses, and provides a plausible link between nutritional environment and the type of adaptive response that results from immunization.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16259011     DOI: 10.1002/eji.200535366

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  31 in total

Review 1.  Chemical mutagenesis: a new strategy against the global threat of infectious diseases.

Authors:  Etienne Richer; Salman T Qureshi; Silvia M Vidal; Danielle Malo
Journal:  Mamm Genome       Date:  2008-06-17       Impact factor: 2.957

2.  γδ Τ cells enhance B cells for antibody production in Hashimoto's thyroiditis, and retinoic acid induces apoptosis of the γδ Τ cell.

Authors:  Hongli Liu; Tingting Zheng; Yufei Mao; Chengcheng Xu; Fei Wu; Ling Bu; Xiao Mou; Yuepeng Zhou; Guoyue Yuan; Shengjun Wang; Tong Zhou; Deyu Chen; Chaoming Mao
Journal:  Endocrine       Date:  2015-05-21       Impact factor: 3.633

3.  New hope offered to reduce GVHD.

Authors:  Yi Zhang
Journal:  Blood       Date:  2021-02-25       Impact factor: 22.113

4.  Treatment with retinoid X receptor agonist IRX4204 ameliorates experimental autoimmune encephalomyelitis.

Authors:  Roshantha As Chandraratna; Randolph J Noelle; Elizabeth C Nowak
Journal:  Am J Transl Res       Date:  2016-02-15       Impact factor: 4.060

Review 5.  Retinoic acid in the immune system.

Authors:  Karina Pino-Lagos; Micah J Benson; Randolph J Noelle
Journal:  Ann N Y Acad Sci       Date:  2008-11       Impact factor: 5.691

6.  SMARTS: reconstructing disease response networks from multiple individuals using time series gene expression data.

Authors:  Aaron Wise; Ziv Bar-Joseph
Journal:  Bioinformatics       Date:  2014-12-04       Impact factor: 6.937

7.  Targeting endothelin ETA and ETB receptors inhibits antigen-induced neutrophil migration and mechanical hypernociception in mice.

Authors:  Waldiceu A Verri; Thiago M Cunha; Danilo A Magro; Ana T G Guerrero; Silvio M Vieira; Vanessa Carregaro; Guilherme R Souza; Maria das Graças M O Henriques; Sérgio H Ferreira; Fernando Q Cunha
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2008-10-15       Impact factor: 3.000

8.  Retinoic acid inhibits CD25+ dendritic cell expansion and γδ T-cell activation in experimental autoimmune uveitis.

Authors:  Dongchun Liang; Aijun Zuo; Hui Shao; Willi K Born; Rebecca L O'Brien; Henry J Kaplan; Deming Sun
Journal:  Invest Ophthalmol Vis Sci       Date:  2013-05-01       Impact factor: 4.799

9.  Retinoic acid inhibits Th17 polarization and enhances FoxP3 expression through a Stat-3/Stat-5 independent signaling pathway.

Authors:  Kevin M Elias; Arian Laurence; Todd S Davidson; Geoffrey Stephens; Yuka Kanno; Ethan M Shevach; John J O'Shea
Journal:  Blood       Date:  2007-10-19       Impact factor: 22.113

10.  9-cis retinoic acid is the ALDH1A1 product that stimulates melanogenesis.

Authors:  Elyse K Paterson; Hsiang Ho; Rubina Kapadia; Anand K Ganesan
Journal:  Exp Dermatol       Date:  2013-03       Impact factor: 3.960

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.